Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in St Germain En Laye – page 115

3 345 clinical trials in St Germain En Laye, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
St Germain En Laye at a glance
3 345
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 345 trials in St Germain En Laye

Open in trial search

Safety and efficacy of efimosfermin alfa versus placebo in adults with compensated cirrhosis (stage F4) due to MASH

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Non-small cell lung cancer+1

Not yet recruiting

Study of setidegrasib (ASP3082) and docetaxel in patients with KRAS G12D‑mutated advanced/metastatic NSCLC after platinum chemo and checkpoint inhibitor

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Astellas Pharma Global Development Inc.

Alcoholic liver disease

Not yet recruiting

Safety and Efficacy of Efimosfermin Alfa vs Placebo in Adults with Alcohol-Related Liver Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Breast cancer+1

Not yet recruiting

Long‑term safety study of alpelisib alone or with fulvestrant in adults with breast cancer who benefited from previous alpelisib treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Study of efimosfermin alfa versus placebo in adults with compensated cirrhosis from metabolic dysfunction-associated steatohepatitis (MASH)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Adenocarcinoma pancreas

Not yet recruiting

First‑Line Study of Zoldonrasib (RMC‑9805) Drug Combination vs Gemcitabine/Nab‑Paclitaxel in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Daraxonrasib
  • Sponsor:Revolution Medicines Inc.

Mucormycosis

Not yet recruiting

Efficacy of isavuconazonium sulfate and amphotericin B drug combination for initial treatment of mucormycosis in adults

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amphotericin B
  • Sponsor:Assistance Publique Hopitaux De Paris

Phase II trial evaluating trastuzumab deruxtecan in patients with HER2‑positive advanced/metastatic cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Centre Leon Berard

Renal transplant

Not yet recruiting

Efficacy of daily high‑dose sulfamethoxazole‑trimethoprim prophylaxis versus low‑dose on bacterial infections in kidney transplant recipients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sulfamethoxazole
  • Sponsor:Assistance Publique Hopitaux De Paris

Phase 2 Randomized Trial of Oral NS-863 in Patients with Pulmonary Arterial Hypertension

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:NS-863
  • Sponsor:Ns Pharma Inc.

Pneumonia+1

Not yet recruiting

Early Use of Dexamethasone versus Sodium Chloride Placebo in Patients with Severe Influenza-Induced Acute Hypoxemic Respiratory Failure (Phase III Randomized Trial)

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Centre Hospital Region Metz Thionville

Plasma cell myeloma

Not yet recruiting

A Phase III Study of AZD0120 versus melphalan hydrochloride with lenalidomide maintenance in transplant‑eligible adults with newly diagnosed multiple myeloma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:AZD0120
  • Sponsor:AstraZeneca AB

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in St Germain En Laye

What the registry says about research in the country

01 Hematologic Oncology

Investigating innovative combination therapies for follicular lymphoma, comparing mosunetuzumab plus lenalidomide against standard treatments to improve progression-free survival in previously untreated patients.

  • Advanced lymphoma treatments
  • Targeted therapy combinations
  • Novel therapeutic approaches

Research focuses on enhancing treatment outcomes for high-risk lymphoma patients.

02 Breast Cancer Research

Evaluating treatment strategies for elderly women with HER2-negative breast cancer, examining the effectiveness of combined chemotherapy and hormone therapy based on genomic profiling.

  • Age-specific treatment protocols
  • Personalized therapy approaches
  • Genomic-guided interventions

Studies aim to optimize treatment outcomes for senior patients while considering their specific needs.

03 Neurological Disorders

Investigating treatment optimization for Secondary Progressive Multiple Sclerosis patients, focusing on the safety and efficacy of disease-modifying therapy withdrawal in stable patients over 50.

  • Treatment discontinuation studies
  • Age-specific MS management
  • Long-term disease monitoring

Research aims to enhance quality of life while maintaining disease stability.

04 Maternal Health

Examining preventive strategies for pregnancy-associated hypertension and pre-eclampsia through controlled trials of acetylsalicylic acid treatment in pregnant women with chronic hypertension.

  • Maternal-fetal outcomes
  • Preventive interventions
  • Pregnancy complications

Focus on reducing maternal and fetal morbidity through preventive care.

05 Endocrine Surgery

Investigating the effects of preoperative cholecalciferol supplementation on post-thyroidectomy outcomes, specifically focusing on preventing hypocalcemia complications.

  • Surgical outcome optimization
  • Preventive supplementation
  • Post-operative care

Research aims to improve patient recovery and reduce hospital stays after thyroid surgery.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.